The following data was compiled by Johns Hopkins University:
Global cases: More than 38.9 million
Global deaths: At least 1.09 million
U.S. cases: More than 7.98 million
U.S. deaths: At least 217,717
Daily new cases reported across the country are rapidly approaching fresh record levels. The U.S. reported more than 63,600 new cases on Thursday, pushing the seven-day average of daily new cases over 53,400, up more than 13% compared with a week ago.
“I’m pretty glum at the moment because it does look as though in the majority of states there’s an increasing number of cases,” Dr. Bill Schaffner, an epidemiologist at Vanderbilt University, said. “There’s a growing sense of coronavirus fatigue out there. People really want to get back to the old normal.” —Will Feuer
WHO finds Remdesivir has ‘little or no effect’ in reducing deaths
Interim results of a study coordinated by the World Health Organization indicated that Gilead Sciences’ remdesivir, along with three other potential coronavirus treatment drugs, had “little or no effect” on death rates among hospitalized patients.
The WHO’s randomized Solidarity Therapeutics Trial was conducted on 11,266 patients, with 2,750 given remdesivir, across 30 countries. It comes a week after Gilead published its own study on remdesivir.
The authors of the WHO study said: “No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.” —Vicky McKeever
Indianapolis Colts close practice facility after positive tests reported
The Indianapolis Colts closed its practice facility after the National Football League team learned several people within its organization tested positive for Covid-19.
The Colts will work remotely and the team is currently in the process of confirming those tests, according to a statement on its website. —Melodie Warner
Gottlieb says Trump should promote responsible mask use
Pfizer targets late-November filing for vaccine’s emergency use approval
In this May 4, 2020 photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer’s COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection.
University of Maryland School of Medicine | AP
Pfizer is targeting late-November to apply for emergency use approval of its Covid-19 vaccine in the U.S., Reuters reports.
Pfizer is developing its vaccine candidate with Germany’s BioNTech and estimated a key safety milestone would be achieved in the third week of November.
That would be the first emergency use approval request for a Covid-19 vaccine, though several coronavirus treatments have already gone through the process. President Donald Trump has repeatedly touted a November timeline for a vaccine while providing few specifics. —Sara Salinas
Read CNBC’s previous live coverage here: